Newsroom | 107049 results
Sorted by: Latest
-
Court Grants Final Approval to Roundup™ Class Settlement
ST. LOUIS--(BUSINESS WIRE)--Today, a Missouri state court granted final approval of the U.S. nationwide class settlement designed to resolve current and future Roundup™ claims alleging non-Hodgkin's lymphoma (NHL) injuries through a long-term claims program. The Court’s final approval order is subject to appeal. The class settlement, combined with the U.S. Supreme Court’s favorable ruling in June in the Durnell case, are mutually reinforcing pillars in the company’s multipronged strategy design...
-
Avenzo Therapeutics Announces Closing of Merger with Rallybio Corporation and Previously Announced $215 Million Concurrent Private Placement
SAN DIEGO--(BUSINESS WIRE)--Avenzo Therapeutics Announces Closing of Merger with Rallybio Corporation and Previously Announced $215 Million Concurrent Private Placement...
-
AN2 Therapeutics to Participate in 9th Annual Evercore Healthcare Conference
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (NASDAQ: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will participate in a fireside chat at the 9th Annual Evercore Healthcare Conference on Wednesday, December 2, 2026 at 8:20am ET and members of management will be available for 1x1 meetin...
-
CareDx to Participate in Upcoming Investor Conferences
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the company will participate in the following investor conferences:Evercore 9th Annual Healthcare Conference at The Loews Coral Gables Hotel in Coral Gables, FL. Fireside chat on Tuesday, December 1, 2026, at 1:45pm ET.Piper Sandler 38th Annual Healthcare Conference at the Lotte New York Palace in New York, NY. Fire...
-
Resumen: Epitech Group y Horus Pharma firman un acuerdo de licencia a escala mundial para el desarrollo del adelmidrol en el ámbito de la salud ocular
NIZA, Francia--(BUSINESS WIRE)--Epitech Group S.p.A., sociedad biofarmacéutica italiana especializada en neuroinflamación, y Horus Pharma, laboratorio francés especializado en oftalmología, anuncian un acuerdo de licencia a escala mundial sobre el adelmidrol, una molécula de la familia de las ALIAmidas desarrollada por Epitech Group. Este acuerdo otorga a Horus Pharma los derechos exclusivos de desarrollo y comercialización del adelmidrol para aplicaciones en oftalmología humana y dermatología...
-
Ataraxis AI to Present Nine Studies at SABCS 2026
NEW YORK--(BUSINESS WIRE)--Ataraxis AI, a company building clinical AI tools to personalize cancer care, announced today that it will present nine studies at the 2026 San Antonio Breast Cancer Symposium (SABCS), including several oral presentations. The research validates Ataraxis AI for prognosis and chemotherapy benefit prediction in the landmark Phase III TAILORx and SWOG-8814 trials and in multi-national real-world cohorts, with head-to-head comparisons against legacy genomic assays. Ataraxi...
-
Epitech Group and Horus Pharma sign a global licensing agreement to develop adelmidrol in eye health
NICE, France--(BUSINESS WIRE)--Epitech Group S.p.A., an Italian biopharmaceutical firm specializing in neuro-inflammation, and Horus Pharma, a French laboratory specializing in ophthalmology, announce a global licensing agreement for adelmidrol, a molecule belonging to the ALIAmide family, developed by Epitech Group. This agreement grants Horus Pharma exclusive rights to develop and market adelmidrol for human ophthalmology and periocular dermatology applications. It aims to explore new approac...
-
Savara Informed That FDA Will Not Take Action on the Molgramostim BLA for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) by the PDUFA Date
YARDLEY, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced that the U.S. Food and Drug Administration (FDA) has communicated that it will not meet the Prescription Drug User Fee Act (PDUFA) target action date of November 22, 2026 for the Company’s molgramostim inhalation solution (molgramostim) Biologics License Application (BLA) for the treatment of autoimmune PAP. The review of the BLA is ongoing...
-
Tenpoint Therapeutics Announces New Drug Submission to Health Canada for the Treatment of Blurry Close-Up Vision (Presbyopia) in Adults
LONDON & WARREN, N.J.--(BUSINESS WIRE)--Tenpoint Therapeutics, Ltd., a global commercial ophthalmic pharmaceutical company focused on developing groundbreaking treatments to improve vision in the aging eye, today announced a New Drug Submission (NDS) to Health Canada for the review and approval of YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% – a once-daily, dual-agent (combination) eye drop – for the treatment of presbyopia in adults. Presbyopia is the gradual lo...
-
CEL-SCI’s Multikine® Receives Saudi FDA NADR Designation, Accelerating Potential Commercial Launch
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI’s Multikine receives Saudi FDA NADR Designation, accelerating potential commercial launch....